Glaxo, Genmab Report Positive Interim Result for Phase III Study of Ofatumumab

By: via Benzinga
GlaxoSmithKline plc (NYSE: GSK) and Genmab A/S announced today that an Independent Data Monitoring Committee (IDMC) interim analysis ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.